Date: 14-Apr-2020

Gracell To Present The First-in-human, Universal TruUCAR™ GC027 Therapy For Relapsed Or Refractory T-cell Acute Lymphoblastic Leukemia At The AACR A

 

SUZHOU, China and SHANGHAIApril 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, is pleased to announce that their first-in-human phase I data of Universal TruUCAR™ GC027 in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) was accepted for plenary oral presentation at the America Association for Cancer Research (AACR) Annual Meeting.

This year's AACR presentations are moved to be held virtually to allow sharing the data in a timely fashion. A series of online sessions featuring presentations will be provided. Gracell will report the clinical safety and efficacy of GC027, an off-the-shelf CAR-T product based on Gracell's TruUCAR™ technology, for treatment of adult T-ALL patients.

"We are very pleased that AACR has accepted the phase I results of GC027, a first-in-human off-the-shelf TruUCAR™ product for plenary oral presentation. Gracell's proprietary TruUCAR™ platform was protected with patents of novel designs and unique features. Remarkably, GC027 derived from HLA unmatched donor's cells, is a monotherapy without co-administration of other immunosuppressive drug." said Dr. William CAO, founder and CEO of Gracell. "We are pleased to share the first-in-human phase I data with the scientific community."

Presentation: Safety and efficacy clinical study of TruUCART™ GC027: the first-in-human, universal CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemia